Search

A study published in the European Journal of Heart Failure compared the effectiveness of sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor (ARNI), with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) in patients with newly diagnosed heart failure (HF) and preserved or mildly reduced ejection fraction. The study used a large real-world dataset from the United States and found that patients initiated on sacubitril/valsartan had significantly lower rates of all-cause and cardiovascular hospitalizations compared to those initiated on ACEi/ARB. These findings support the potential benefit of early initiation of sacubitril/valsartan in a diverse and high-risk HF population. However, the study acknowledges limitations, including its retrospective nature and the possibility of unmeasured confounding. The study was funded by Novartis AG, and some of the authors reported conflicts of interest. [Extracted from the article]